Targeting Leukemic Stem Cells
靶向白血病干细胞
基本信息
- 批准号:8309338
- 负责人:
- 金额:$ 41.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-25 至 2014-07-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAntibodiesApoptosisBindingBiological AssayBiologyBlast PhaseBloodCD34 AntigensCD34 geneCell CountCell CycleCell LineCell physiologyCellsCharacteristicsChemotherapy-Oncologic ProcedureChronic Myeloid LeukemiaClinical TrialsComplexDNADependenceDevelopmentDiseaseDrug KineticsDrug resistanceEngineeringFailureGene AbnormalityGene ExpressionGene Transduction AgentGenesGoalsHematological DiseaseHematopoietic stem cellsHumanIn VitroLaser Scanning CytometryLeadLeftLeukemic CellMalignant - descriptorMalignant NeoplasmsMediatingMethodsModelingMusMyelogenousNOD/SCID mouseOncogenesOrganPatientsPopulationPropertyProtaminesProteinsRNARecombinantsRelapseResearchResistance developmentRouteSafetySamplingSmall Interfering RNASpecificityStagingStem Cell FactorStem cellsSurfaceSystemSystems DevelopmentTestingTimeTissuesTransgenic MiceTreatment FailureViral VectorXenograft procedureantigenebasebcr-abl Fusion Proteinscancer cellcancer stem cellcancer therapycell growthcell typedosageeffective therapyembryonic stem cellgene therapyhuman stem cellsin vivoin vivo Modelleukemialeukemic stem cellmouse modelnon-viral gene therapynovelpreventprotein expressionreagent testingresearch studyself-renewaltherapy developmenttumor
项目摘要
DESCRIPTION (provided by applicant): Although advances in our understanding of gene abnormalities in diseases involving blood organs and other tissues has been remarkable in recent years, the ability to introduce or manipulate expression of genes in target cells through gene therapy methods has been limited. Although a number of powerful viral vectors have been developed and utilized in both experimental and human systems, a number of issues, particularly safety, have demonstrated the need to develop non-viral based vectors for gene therapy. Recent discoveries have also demonstrated that it is essential to target normal hematopoietic stem cells (HSC), cells which have the potential to both self-renew and to give rise to all cell types in a given tissue, as well as leukemic stem cells (LSC), a subpopulation of cancer cells which confer the self-renewal properties of the malignant leukemic clone. Normal human HSC, and a majority of LSC, express the stem cell antigen CD34, and this proposal will utilize the specificity of this surface marker, as well as a novel murine model in which murine HSC express the human CD34 antigen. Therefore, the long range goals of this project are to develop novel non-viral gene therapy methods targeting normal and leukemic stem cells. In order to accomplish these goals, we propose the following Specific Aims: (1) to test human CD34 antibody mediated siRNA delivery in human CD34 cell lines; (2) to test human CD34 antibody mediated siRNA in murine models in vivo; and (3) to test whether human CD34 antibody mediated silencing of BCR/ABL or SALL4 will
inhibit proliferation and leukemia-initiating ability of human primary myeloid LSCs. Accomplishment of these goals will set the stage for clinical trials, as well as lead to development of therapies directed against other oncogenes as well as altering stem cell gene expression.
描述(申请人提供):尽管近年来我们对涉及血液、器官和其他组织的疾病的基因异常的了解取得了显著进展,但通过基因治疗方法在靶细胞中引入或操纵基因表达的能力一直受到限制。虽然许多强大的病毒载体已经被开发并在实验和人类系统中使用,但一些问题,特别是安全性,已经证明了开发用于基因治疗的非病毒载体的必要性。最近的发现也表明,靶向正常的造血干细胞(HSC)以及白血病干细胞(LSC)是至关重要的,HSC是一种具有自我更新能力并在特定组织中产生所有细胞类型的细胞,白血病干细胞是一种具有恶性白血病克隆自我更新特性的癌细胞亚群。正常人HSC和大多数LSC表达干细胞抗原CD34,本研究将利用这一表面标志的特异性,以及一种新的小鼠HSC表达人CD34抗原的模型。因此,该项目的长期目标是开发针对正常和白血病干细胞的新型非病毒基因治疗方法。为了实现这些目标,我们提出了以下具体目标:(1)检测人CD34抗体介导的siRNA在人CD34细胞系中的传递;(2)在小鼠体内模型中检测人CD34抗体介导的siRNA;以及(3)检测人CD34抗体介导的bcr/abl或SALL4沉默是否
抑制人原代髓系LSCs的增殖和白血病形成能力。这些目标的实现将为临床试验奠定基础,并导致针对其他癌基因的治疗方法的开发,以及改变干细胞基因的表达。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DANIEL G TENEN其他文献
DANIEL G TENEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DANIEL G TENEN', 18)}}的其他基金
Project 3 - Transcriptional and epigenetic heterogeneity of stem/progenitor cells
项目 3 - 干/祖细胞的转录和表观遗传异质性
- 批准号:
10641542 - 财政年份:2017
- 资助金额:
$ 41.81万 - 项目类别:
Noncoding RNA-DNMT1 interactions in hematopoiesis
非编码 RNA-DNMT1 在造血过程中的相互作用
- 批准号:
9279117 - 财政年份:2015
- 资助金额:
$ 41.81万 - 项目类别:
Mechanisms of regulation by RNA in acute myeloid leukemia
RNA在急性髓系白血病中的调控机制
- 批准号:
10215241 - 财政年份:2015
- 资助金额:
$ 41.81万 - 项目类别:
Noncoding RNA-DNMT1 interactions in hematopoiesis
非编码 RNA-DNMT1 在造血过程中的相互作用
- 批准号:
9087226 - 财政年份:2015
- 资助金额:
$ 41.81万 - 项目类别:
ONCOGENESIS AND MYELOID TRANSCRIPTION FACTORS IN AML
AML 中的癌发生和骨髓转录因子
- 批准号:
8254467 - 财政年份:2011
- 资助金额:
$ 41.81万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 41.81万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 41.81万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 41.81万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 41.81万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 41.81万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 41.81万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 41.81万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 41.81万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 41.81万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 41.81万 - 项目类别:














{{item.name}}会员




